Phio Pharmaceuticals Corp Total Liabilities
Phio Pharmaceuticals Corp total liabilities. Based on the latest financial reports, Phio Pharmaceuticals Corp (PHIO) has total liabilities worth $950.00K USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PHIO asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Phio Pharmaceuticals Corp (2011–2025)
Total liabilities of Phio Pharmaceuticals Corp from 2011 to 2025. This chart illustrates how Phio Pharmaceuticals Corp's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Phio Pharmaceuticals Corp's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Phio Pharmaceuticals Corp Competitors by Total Liabilities
The table below lists competitors of Phio Pharmaceuticals Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SAGTEC GLOBAL LIMITED Ordinary shares
NASDAQ:SAGT
|
USA | $14.64 Million |
|
Global Surfaces Limited
NSE:GSLSU
|
India | Rs-2.71 Billion |
|
VitzroSys Co Ltd
KQ:054220
|
Korea | ₩35.27 Billion |
|
YOC AG
F:YOC
|
Germany | €13.25 Million |
|
UDAYSHIVAKUMAR INFRA ORD (BSE)
NSE:USK
|
India | Rs1.64 Billion |
|
Kohinoor Foods Limited
NSE:KOHINOOR
|
India | Rs1.86 Billion |
|
Dfcity Group Bhd
KLSE:5165
|
Malaysia | RM24.25 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Phio Pharmaceuticals Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Phio Pharmaceuticals Corp asset portfolio.
Liquidity & Leverage Metrics
Phio Pharmaceuticals Corp Total Liabilities Ratios Explained
Phio Pharmaceuticals Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 66.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Phio Pharmaceuticals Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Phio Pharmaceuticals Corp (2011–2025)
The table below shows the annual total liabilities of Phio Pharmaceuticals Corp from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.34 Million | +32.02% |
| 2024-12-31 | $1.01 Million | -37.88% |
| 2023-12-31 | $1.63 Million | -17.22% |
| 2022-12-31 | $1.97 Million | -39.04% |
| 2021-12-31 | $3.24 Million | +18.96% |
| 2020-12-31 | $2.72 Million | +18.81% |
| 2019-12-31 | $2.29 Million | +31.36% |
| 2018-12-31 | $1.74 Million | -23.00% |
| 2017-12-31 | $2.27 Million | -10.90% |
| 2016-12-31 | $2.54 Million | +12.03% |
| 2015-12-31 | $2.27 Million | -64.79% |
| 2014-12-31 | $6.44 Million | -35.53% |
| 2013-12-31 | $10.00 Million | -12.56% |
| 2012-12-31 | $11.43 Million | +401.18% |
| 2011-12-31 | $2.28 Million | -- |
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene ex… Read more